Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 2, 2026 · Investor press release · Financial statements
GYRE THERAPEUTICS, INC.
49
Investor press release
Jun 2, 2026
| Item 7.01 | Regulation FD disclosure (investor press release or presentation) |
| Item 9.01 | Financial statements and exhibits |
GYRE THERAPEUTICS, INC. filed this to release information to investors under Regulation FD, usually a press release, conference presentation, or other event the company considers important. 1 A Fully-Integrated Biopharmaceutical Company Focused on Fibrosis, Inflammatory Diseases and Cancer This presentation contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regar…
The filing reports Items 7.01, 9.01. None of these codes are typically workforce-tagged, but analysts still review them for indirect labor-market signals.
GYRE THERAPEUTICS, INC. filed this 8-K with the SEC. cutoffs links it to the employer's layoff history, visa filings, and other labor-market signals.
